Phase I/Ii Dose-Escalation Study Of 225Ac-J591 In Progressive Mcrpc

Phase I/II dose-escalation study of 225Ac-J591 in progressive mCRPC

Phase I dose-escalation study of fractionated dose 225Ac J591 for mCRPC

Scott Tagawa, MD, shares results of phase 1 dose escalation study of 225Ac-J591 in mPC patients

A phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive mCRPC

A single fractionated cycle of 225Ac-J591 shows preliminary efficacy on mCRPC patients

PSMA-TRT, 225Ac-J591 and 177Lu-PSMA I&T in mCRPC

Results of Phase I Study Reach Primary End Point for mCRPC

Targeted Oncology

Phase I Trial Of 225Ac-J591 In Metastatic Castration-Resistant Prostate Cancer

Targeting PSMA in mCRPC

PSMA-targeted alpha emitter 225Ac-J591 for mCRPC

Phase I/II Trial of 177Lu−J591 and 177Lu−PSMA−617 in mCRCP

Fractionated dose 177Lu-PSMA-617 in patients with mCRPC

ASC2ESCALATE: dose escalation study of asciminib in second-line CP-CML

VJHemOnc – Video Journal of Hematology & HemOnc

Phase I trial of ARX517, an anti-PSMA ADC, in mCRPC

PSMA ADC in prostate cancer: Phase I results

Prostate Cancer Consumer session at #ProsTIC22

VISION: 177Lu-PSMA-617 in PSMA-positive mCRPC

Bill Gates' Treatment For Cancer a Potential Lifesaver

Bill Gates BuzzNews

Scott Tagawa, MD, on the Impact of Racial Disparity and COVID-19 on Prostate Cancer Clinical Trials